143 related articles for article (PubMed ID: 35944461)
1. Neobavaisoflavone inhibits antitumor immunosuppression via myeloid-derived suppressor cells.
Guo J; Shen Y; Hu S; Rui T; Liu J; Yuan Y
Int Immunopharmacol; 2022 Oct; 111():109103. PubMed ID: 35944461
[TBL] [Abstract][Full Text] [Related]
2. Neobavaisoflavone-mediated T
Guo J; Qiao C; Zhou J; Hu S; Lin X; Shen Y; Li Z; Liu J
Int Immunopharmacol; 2021 Dec; 101(Pt A):108191. PubMed ID: 34601328
[TBL] [Abstract][Full Text] [Related]
3. Developing neobavaisoflavone nanoemulsion suppresses lung cancer progression by regulating tumor microenvironment.
Ye H; He X; Feng X
Biomed Pharmacother; 2020 Sep; 129():110369. PubMed ID: 32563983
[TBL] [Abstract][Full Text] [Related]
4. Prim-O-glucosylcimifugin enhances the antitumour effect of PD-1 inhibition by targeting myeloid-derived suppressor cells.
Gao W; Zhang X; Yang W; Dou D; Zhang H; Tang Y; Zhong W; Meng J; Bai Y; Liu Y; Yang L; Chen S; Liu H; Yang C; Sun T
J Immunother Cancer; 2019 Aug; 7(1):231. PubMed ID: 31462297
[TBL] [Abstract][Full Text] [Related]
5. Shuangshen granules attenuate lung metastasis by modulating bone marrow differentiation through mTOR signalling inhibition.
Wei H; Guo C; Zhu R; Zhang C; Han N; Liu R; Hua B; Li Y; Lin H; Yu J
J Ethnopharmacol; 2021 Dec; 281():113305. PubMed ID: 32890710
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of curcumin on myeloid-derived suppressor cells is requisite for controlling lung cancer.
Liu D; You M; Xu Y; Li F; Zhang D; Li X; Hou Y
Int Immunopharmacol; 2016 Oct; 39():265-272. PubMed ID: 27497194
[TBL] [Abstract][Full Text] [Related]
7. Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade.
Grauers Wiktorin H; Nilsson MS; Kiffin R; Sander FE; Lenox B; Rydström A; Hellstrand K; Martner A
Cancer Immunol Immunother; 2019 Feb; 68(2):163-174. PubMed ID: 30315349
[TBL] [Abstract][Full Text] [Related]
8. Gansui-Banxia Decoction extraction inhibits MDSCs accumulation via AKT /STAT3/ERK signaling pathways to regulate antitumor immunity in C57bl/6 mice.
Feng XY; Chen BC; Li JC; Li JM; Li HM; Chen XQ; Liu D; Li RT
Phytomedicine; 2021 Dec; 93():153779. PubMed ID: 34638030
[TBL] [Abstract][Full Text] [Related]
9. Targeting Inhibition of Accumulation and Function of Myeloid-Derived Suppressor Cells by Artemisinin via PI3K/AKT, mTOR, and MAPK Pathways Enhances Anti-PD-L1 Immunotherapy in Melanoma and Liver Tumors.
Zhang M; Wang L; Liu W; Wang T; De Sanctis F; Zhu L; Zhang G; Cheng J; Cao Q; Zhou J; Tagliabue A; Bronte V; Yan D; Wan X; Yu G
J Immunol Res; 2022; 2022():2253436. PubMed ID: 35785030
[TBL] [Abstract][Full Text] [Related]
10. The blockage of Notch signalling promoted the generation of polymorphonuclear myeloid-derived suppressor cells with lower immunosuppression.
Wang SH; Lu QY; Guo YH; Song YY; Liu PJ; Wang YC
Eur J Cancer; 2016 Nov; 68():90-105. PubMed ID: 27728841
[TBL] [Abstract][Full Text] [Related]
11. CXCL17-derived CD11b
Hsu YL; Yen MC; Chang WA; Tsai PH; Pan YC; Liao SH; Kuo PL
Breast Cancer Res; 2019 Feb; 21(1):23. PubMed ID: 30755260
[TBL] [Abstract][Full Text] [Related]
12. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X
Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739
[TBL] [Abstract][Full Text] [Related]
13. The Role of Myeloid-Derived Suppressor Cells in Tumor Growth and Metastasis.
Bayik D; Lee J; Lathia JD
Exp Suppl; 2022; 113():189-217. PubMed ID: 35165865
[TBL] [Abstract][Full Text] [Related]
14. Serum inhibits the immunosuppressive function of myeloid-derived suppressor cells isolated from 4T1 tumor-bearing mice.
Hamilton MJ; Banáth JP; Lam V; Lepard NE; Krystal G; Bennewith KL
Cancer Immunol Immunother; 2012 May; 61(5):643-54. PubMed ID: 22021068
[TBL] [Abstract][Full Text] [Related]
15. Cisplatin inhibits frequency and suppressive activity of monocytic myeloid-derived suppressor cells in cancer patients.
Van Wigcheren GF; De Haas N; Mulder TA; Horrevorts SK; Bloemendal M; Hins-Debree S; Mao Y; Kiessling R; van Herpen CML; Flórez-Grau G; Hato SV; De Vries IJM
Oncoimmunology; 2021; 10(1):1935557. PubMed ID: 34239773
[TBL] [Abstract][Full Text] [Related]
16. Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.
Dysthe M; Parihar R
Adv Exp Med Biol; 2020; 1224():117-140. PubMed ID: 32036608
[TBL] [Abstract][Full Text] [Related]
17. A Complex Metabolic Network Confers Immunosuppressive Functions to Myeloid-Derived Suppressor Cells (MDSCs) within the Tumour Microenvironment.
Hofer F; Di Sario G; Musiu C; Sartoris S; De Sanctis F; Ugel S
Cells; 2021 Oct; 10(10):. PubMed ID: 34685679
[TBL] [Abstract][Full Text] [Related]
18. [Circulating Myeloid Suppressor Cells and Their Role in Tumour Immunology].
Pilatova K; Budinská E; Bensciková B; Nenutil R; Šefr R; Fedorová L; Hanáková B; Brychtová V; Zdražilová Dubská L
Klin Onkol; 2017; 30(Supplementum1):166-169. PubMed ID: 28471197
[TBL] [Abstract][Full Text] [Related]
19. Phytochemicals inhibit the immunosuppressive functions of myeloid-derived suppressor cells (MDSC): Impact on cancer and age-related chronic inflammatory disorders.
Salminen A; Kaarniranta K; Kauppinen A
Int Immunopharmacol; 2018 Aug; 61():231-240. PubMed ID: 29894862
[TBL] [Abstract][Full Text] [Related]
20. Myeloid-Derived Suppressor Cells as a Therapeutic Target for Cancer.
Law AMK; Valdes-Mora F; Gallego-Ortega D
Cells; 2020 Feb; 9(3):. PubMed ID: 32121014
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
